Physician profile
Abdul Latif Bikak
NPI 1578827234
$213,677.70
in general payments reported to CMS, 2019-2025
31 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $405 · 2021: $964 · 2022: $8,228 · 2023: $8,865 · 2024: $64K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Travel and Lodging: $22K · Food and Beverage: $8,411 · Consulting Fee: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $170,215.00 |
| Travel and Lodging | $21,633.33 |
| Food and Beverage | $8,410.89 |
| Consulting Fee | $2,557.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $164,986.49 | 2019-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,989.79 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $12,116.31 | 2022-2025 | Jardiance |
| Pfizer INC. | $7,068.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $4,386.15 | 2021-2025 | Lokelma, Wainua, Farxiga |
| Abbott Laboratories | $3,019.89 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Xience Skypoint, Mitraclip |
| Abiomed | $715.23 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $610.95 | 2019-2025 | Lifevest |
| Cvrx, INC. | $544.23 | 2023-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $542.67 | 2019-2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $454.19 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $422.20 | 2022-2025 | Verquvo, Winrevair |
| United Therapeutics Corporation | $232.46 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Impulse Dynamics (USA) INC. | $196.92 | 2022-2025 | Optimizer, Optimizer |
| Edwards Lifesciences Corporation | $182.31 | 2024 | Sapien 3 Ultra Resilia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procyrion, INC. | $171.22 | 2024-2025 | Aortix System |
| E.R. Squibb & Sons, L.L.C. | $159.75 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $132.15 | 2021-2025 | |
| Medtronic Vascular, INC. | $125.19 | 2019-2020 | |
| Medtronic, INC. | $123.36 | 2022 | |
| Amgen INC. | $94.71 | 2019-2022 | |
| Boston Scientific Corporation | $75.10 | 2024 | Avvigo Guidance System |
| Scpharmaceuticals INC. | $63.86 | 2023-2025 | |
| Daiichi Sankyo INC. | $47.85 | 2021-2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $46.52 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $43.05 | 2019-2022 | |
| Novo Nordisk INC | $40.71 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Akcea Therapeutics, INC. | $30.92 | 2019 | |
| Sandoz INC. | $22.10 | 2023 | Treprostinil |
| Phadia US INC. | $19.52 | 2023 | Immunocap |
| Ge Healthcare | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Latif Bikak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.